Pfizer apoya los biogenéricos

NEW YORK (AP) — With Pfizer Inc. about to acquire rival drugmaker Wyeth and its expertise in making pricey and complex biologic drugs, Pfizer CEO Jeffrey Kindler strongly supports allowing generic versions of them.

"Done right, with regard to the safety of the products, biological follow-ons are a very appropriate thing to do," he said in an interview Wednesday with The Associated Press. "We support that, especially because we're now buying a large biotech operation."

Wyeth's biologic products include the blockbuster arthritis medicine Enbrel, cancer drug Mylotarg and hemophilia treatments BeneFix and ReFacto. Pfizer has 17 biologic drugs in development but sells only one, Macugen for macular degeneration.

Mas...